Patient Satisfaction Following Twice Daily Dosing With DFD-01 in Subjects With Moderate Plaque Psoriasis
An Open-Label, Multicenter Study of Patient-Reported Satisfaction Following Twice Daily Dosing With Betamethasone Dipropionate Spray, 0.05% in Subjects With Moderate Plaque Psoriasis
Sponsor: Primus Pharmaceuticals
Listed as NCT02749799, this PHASE4 trial focuses on Plaque Psoriasis and remains completed. Sponsored by Primus Pharmaceuticals, it has been updated 9 times since 2016, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Apr 2024 — Jul 2024 [monthly]
Completed PHASE4
-
Mar 2021 — Apr 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Mar 2021 [monthly]
Completed PHASE4
▶ Show 4 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Completed PHASE4
Phase: PHASE3 → PHASE4
-
Jun 2018 — Nov 2020 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Feb 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Primus Pharmaceuticals
- Prosoft Clinical
For direct contact, visit the study record on ClinicalTrials.gov .